NCT03662204 is a clinical trial of Blood Sample Collection in Breast Cancer, sponsored by Exact Sciences Corporation.

Who is sponsoring NCT03662204?

NCT03662204 is sponsored by Exact Sciences Corporation.

What drugs are being tested in NCT03662204?

Interventions in NCT03662204: Blood Sample Collection.

What condition does NCT03662204 study?

NCT03662204 studies Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney Cancer, Renal Pelvis Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer.

Is NCT03662204 still recruiting?

NCT03662204 is currently completed. Last updated 1 September 2022.

Last reviewed 2022-09-01 · How we verify

NCT03662204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Completed Last updated 1 September 2022

What this trial tests

trial testing Blood Sample Collection in Breast Cancer in 5,133 participants. Completed in 31 March 2022.

Timeline

23 August 2018

Primary endpoint
31 March 2022

31 March 2022

Quick facts

Lead sponsor	Exact Sciences Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5,133
Start date	23 August 2018
Primary completion	31 March 2022
Estimated completion	31 March 2022
Sites	119 locations across United States

Drugs / interventions tested

Blood Sample Collection — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Lung Cancer — all drugs for Lung Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →
Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Exact Sciences Corporation

Who can join

18 and older, any sex, with Breast Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.
Xie H, Mahoney DW, Foote PH, Burger KN, et al · · 2021 · cited 23× · PMID 33028593 · DOI 10.1158/1078-0432.ccr-20-2589
Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma.
Thompson JK, Bednar F. · · 2021 · cited 4× · PMID 34968245 · DOI 10.3390/epigenomes5040020

Verify or expand the search:

Other trials of Blood Sample Collection

Trials testing the same drug.

NCT07436637 — Guardant Shield Colorectal Cancer Screening · NA · not yet recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting
NCT07405515 — Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19 · NA · active not recruiting
NCT05487248 — A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients · NA · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Exact Sciences Corporation trials

Trials by the same sponsor.

NCT05246839 — Informed Choice - Compass · terminated
NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03662204 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
Last refreshed: 1 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03662204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing